AKT1 and acute lymphoblastic leukemia: Our data indicate that besides Ph+ ALL, other subtypes of ALL with constitutive activation of FOXM1 downstream of AKT (for example, owing to the oncogenic activation of the Ras–MAPK pathway) are sensitive to FOXM1 inhibition as well and validate FOXM1 as a therapeutic target in a large fraction of drug-resistant B-cell lineage ALL.